Basic Information



GTO ID GTC3997
Trial ID NCT03896568
Disease Brain Glioma
Altered gene E1A|RGD
Therapeutic/Target gene Therapeutic gene
TherapyDNA oncolytic virus
Treatment Ad5-Delta 24RGD|DNX-2401|tasadenoturev
PhasePhase1
Recruitment statusRecruiting
TitlePhase I Clinical Trial of Allogeneic Bone Marrow Human Mesenchymal Stem Cells Loaded With A Tumor Selective Oncolytic Adenovirus, DNX-2401, Administered Via Intra-Arterial Injection in Patients With Recurrent High-Grade Glioma
Year2019
CountryUnited States
Company sponsorM.D. Anderson Cancer Center
Other ID(s)2015-0953|NCI-2019-01195|2015-0953
Vector information
VectorMesenchymal stem cell
ConstructAd5-Delta 24RGD
Vector typetumor-selective, replication-competent oncolytic adenovirus
Transgene/Inserted geneRGD-motif, which was engineered into the fiber H-loop, enabling the virus to use αvβ3 or αvβ5 integrins to enter cells.
Regulatory elementRGD-motif
Viral genome modification24-base-pair deletion in the E1A gene
Additional featureMesenchymal stem cells as carriers

Clinical Result

Cohort 1
Administration route intraarterial injection
Pts 36
Age Adult, Older_Adult
References PMID: 34824133

Relationship Graph

Overview of Knowledge Graph